SCHEMBL4156367

SCHEMBL4156367

N#Cc1ccc(Cn2cc(-c3cccs3)c(=O)[nH]c2=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.43
PIM1 P11309 1/20 0.43
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 3/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
PKM P14618 2/20 0.40
PRNP P04156 2/20 0.40
RXFP1 Q9HBX9 2/20 0.40
USP2 O75604 1/20 0.40
POLB P06746 1/20 0.40
BLM P54132 1/20 0.40
SAE1 Q9UBE0 1/20 0.40
UBA2 Q9UBT2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
P2RY2 P41231 1/20 0.38
ALDH1A1 P00352 2/20 0.37
NPM1 P06748 1/20 0.37
MAPT P10636 1/20 0.37
CYP11B1 P15538 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4167699 0.88 L3MBTL1 (0.44) KDM4EPIM1HPGDPOLBL3MBTL1
SCHEMBL4162503 0.85 HPGD (0.56) KDM4EHPGDKMT2AMEN1POLB
SCHEMBL4173284 0.84 HPGD (0.43) HPGDKMT2AMEN1PKMUSP2
SCHEMBL4167785 0.77 KDM4E (0.48) KDM4EHPGDNPSR1KMT2AMEN1
SCHEMBL4172004 0.75 HPGD (0.44) HPGDKMT2AMEN1BLMCYP11B1
SCHEMBL2496260 0.74 P2RY2 (0.41) KDM4EPIM1HPGDKMT2AMEN1
SCHEMBL2492788 0.73 P2RY2 (0.40) KDM4EHPGDNPSR1KMT2AMEN1
SCHEMBL1507793 0.68 NPSR1 (0.47) NPSR1KMT2ACYP11B1CYP11B2
SCHEMBL4162994 0.68 KMT2A (0.53) KDM4EHPGDNPSR1KMT2AMEN1
SCHEMBL7834032 0.66 SMN1; SMN2 (0.64) KDM4EHPGDKMT2AMEN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US claimed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO claimed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO disclosed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS TK1, LCK, FYN KDM4E 2284/4885PIM1 663/4885HPGD 1010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.